Premium
Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer
Author(s) -
Yap HweeYong,
Blumenschein George R.,
Tashima Charles K.,
Hortobagyi Gabriel N.,
Buzdar Aman U.,
Wiseman Charles L.
Publication year - 1979
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197907)44:1<32::aid-cncr2820440106>3.0.co;2-3
Subject(s) - medicine , refractory (planetary science) , methotrexate , chemotherapy , vincristine , breast cancer , complete remission , surgery , toxicity , combination chemotherapy , oncology , cyclophosphamide , cancer , gastroenterology , physics , astrobiology
Eighteen patients with advanced breast cancer refractory to combination chemotherapy with 5‐FU, Adriamycin, Cytoxan (FAC) were treated with methotrexate 30 to 40 mg/m 2 iv and vincristine 1.5 mg/m 2 iv at weekly intervals. Of 17 evaluable patients, 4 (23%) achieved a partial remission with a median duration of remission of 6 months and a median survival of 10 months. In another seven of seventeen patients (41%) the disease remained stable. Toxicity was minimal.